Avidity Biosciences, Inc.(RNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RNA Avidity Biosciences, Inc.

Post-Market Trading 11-22 16:11:02 EST

43.24

+0.68

+1.60%

盘后43.25

+0.01+0.02%

16:02 EST

High44.02	Low41.75	Vol986.71K
Open42.50	D1 Closing42.56	Amplitude5.33%
Mkt Cap5.16B	Tradable Cap4.00B	Total Shares119.31M
T/O42.46M	T/O Rate1.07%	Tradable Shares92.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"RNA","market":"US","secType":"STK","nameCN":"Avidity Biosciences, Inc.","latestPrice":43.24,"timestamp":1732309199999,"preClose":42.56,"halted":0,"volume":986712,"hourTrading":{"tag":"盘后","latestPrice":43.25,"preClose":43.24,"latestTime":"16:02 EST","volume":19194,"amount":830140.5,"timestamp":1732309341528},"delay":0,"floatShares":92434797,"shares":119309317,"eps":-2.851578,"marketStatus":"Post-Market Trading","change":0.68,"latestTime":"11-22 16:11:02 EST","open":42.5,"high":44.02,"low":41.75,"amount":42462775.96944,"amplitude":0.053336,"askPrice":44.1,"askSize":100,"bidPrice":42,"bidSize":4,"shortable":3,"etf":0,"ttmEps":-2.851578,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732323600000},"marketStatusCode":4,"adr":0,"listingDate":1591934400000,"exchange":"NASDAQ","adjPreClose":42.56,"preHourTrading":{"tag":"盘前","latestPrice":42.73,"preClose":42.56,"latestTime":"09:27 EST","volume":13,"amount":553.130006,"timestamp":1732285670029},"postHourTrading":{"tag":"盘后","latestPrice":43.25,"preClose":43.24,"latestTime":"16:02 EST","volume":19194,"amount":830140.5,"timestamp":1732309341528},"volumeRatio":0.865997,"impliedVol":0.5471,"impliedVolPercentile":0.1151},"requestUrl":"/m/hq/s/RNA","defaultTab":"news","newsList":[{"id":"2485428404","title":"Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2485428404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485428404?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:05","pubTimestamp":1732223101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA77C8TP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNA","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210149790.SGD","BK4139","IE00B64PRP62.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4585","BK4588","NDAQ","BK4505","BK4112","LU2095319765.USD"],"gpt_icon":0},{"id":"2485428278","title":"Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2485428278","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485428278?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:05","pubTimestamp":1732223100,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov. 21, 2024 /PRNewswire/ --Avidity Biosciences, Inc. , a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates , today announced that onNovember 20, 2024,the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 117,000 shares of its common stock and 58,500 restricted stock units  to twelve  new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan . The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MPQ_41DhqhHuW4qoOGYzoA--~B/aD0xODg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/d3ba411dafc5b9fe6b77b592275c9c79","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MPQ_41DhqhHuW4qoOGYzoA--~B/aD0xODg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/d3ba411dafc5b9fe6b77b592275c9c79"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/avidity-biosciences-announces-inducement-grants-210500984.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avidity-biosciences-announces-inducement-grants-210500984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU2095319765.USD","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","RNA","BK4139","IE00B3QW5Z07.USD","IE00BKPKM429.USD","NDAQ","BK4505","BK4112","BK4588",".IXIC"],"gpt_icon":0},{"id":"2485423662","title":"Korro to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2485423662","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485423662?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:01","pubTimestamp":1732222860,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Nov.  21, 2024  (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/21/2985602/0/en/Korro-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","RNA","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2485498833","title":"Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2485498833","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485498833?lang=en_us&edition=fundamental","pubTime":"2024-11-21 20:30","pubTimestamp":1732192200,"startTime":"0","endTime":"0","summary":"-REWRITE study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of KRRO-110 -First participant dosing anticipated in the first quar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/21/2985116/0/en/Korro-Receives-Australian-HREC-Approval-and-CTN-Clearance-to-Initiate-Phase-1-2a-Clinical-Study-REWRITE-of-KRRO-110-for-Alpha-1-Antitrypsin-Deficiency.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","BK4588","BK4585","BK4505","BK4139","KRRO","RNA","TGA"],"gpt_icon":0},{"id":"2485486986","title":"2 ASX healthcare shares having a stellar run today","url":"https://stock-news.laohu8.com/highlight/detail?id=2485486986","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485486986?lang=en_us&edition=fundamental","pubTime":"2024-11-21 10:52","pubTimestamp":1732157578,"startTime":"0","endTime":"0","summary":"ASX healthcare shares are currently in the red on Thursday, with theS&P/ASX 200 Health Care Index(ASX: XHJ) down 0.2% and the broaderS&P/ASX 200 Index(ASX: XJO) 0.18% lower. However, two ASX healthcar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/21/2-asx-healthcare-shares-having-a-stellar-run-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4139","BK4588","XJO.AU","SIG.AU","RNA","BK7508","BK7067","BK4505","BK4585","RAC.AU","BK7103"],"gpt_icon":0},{"id":"2485107336","title":"Race Oncology Completes Drug Discovery Program at Monash University; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485107336","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485107336?lang=en_us&edition=fundamental","pubTime":"2024-11-21 09:38","pubTimestamp":1732153121,"startTime":"0","endTime":"0","summary":"Race Oncology  completed a drug discovery program targeting the Fat and Obesity associated  protein at Monash University's Fragment Platform, according to a Thursday filing with the Australian bourse.The program used nuclear magnetic resonance screening to identify 39 chemical candidates that bind specifically to the FTO protein, the filing said.The FTO protein is a key regulator in ribonucleic acid  epigenetics. Loss of control of RNA epigenetics is linked to several cancers and metabolic diseases.The identification of the chemical candidates by Race Oncology provides a platform for developing new FTO-targeting drugs, the filing said.Race Oncology plans to advance these candidates into a hit-to-lead medicinal chemistry program, though a final decision has not yet been made on progressing this expensive phase.The company's shares rose almost 3% in recent Thursday trade.Price : $1.40, Change: $+0.04, Percent Change: +2.94%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","RNA","LU0345774631.USD","BK4125","BK7508","BK4588","LU1043141123.HKD","BK7067","BK4139","BK4585","LU0426417589.USD","RAC.AU","AUD","LU0994945656.USD","LU2238339852.HKD","LU0426412945.USD"],"gpt_icon":0},{"id":"2484956973","title":"Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2484956973","media":"Business Wire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484956973?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:15","pubTimestamp":1731982500,"startTime":"0","endTime":"0","summary":"– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 –。– Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts –。– Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares –。– Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 –。These data were presented in an oral session at the American Association for the Study of Liver Diseases  The Liver Meeting, in San Diego, CA. Based on these results, and following a recent meeting with the FDA, Vir Biotechnology plans to initiate the Phase 3 registrational ECLIPSE program in the first half of 2025 to further evaluate the combination of tobevibart and elebsiran for the treatment of CHD.Primary Endpoint Analysis from the Phase 2 SOLSTICE Tria","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/l5oi2o6BXS3LWePoIaxyng--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4cd04e41299f5f946a2db3e8d5341040","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/l5oi2o6BXS3LWePoIaxyng--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4cd04e41299f5f946a2db3e8d5341040"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-presents-positive-chronic-021500234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4568","BK4585","BK4539","CHD","ALT","BK4588","COMP","HDV","LU1878469433.USD","VIR","BK4535","BK4018","RNA","BK4504","BK4505","BK4079"],"gpt_icon":0},{"id":"2484322639","title":"Arcturus Therapeutics to Present at Jefferies London Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2484322639","media":"Business Wire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484322639?lang=en_us&edition=fundamental","pubTime":"2024-11-19 09:00","pubTimestamp":1731978000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, November 19, 2024----Arcturus Therapeutics Holdings Inc. , a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, on Wednesday, November 20, 2024, at 9:30 am GMT.Arcturus TherapeuticsPublic Relations & Investor RelationsNeda SafarzadehVP, Head of Investor Relations/PR & Marketing 900-2682IR@ArcturusRx.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ayEV.42liLzOxEkKDS7rkQ--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/5d70676411f8e76fdafb7bfbe3001f8f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ayEV.42liLzOxEkKDS7rkQ--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/5d70676411f8e76fdafb7bfbe3001f8f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-present-jefferies-london-010000794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNA","BK4093","BK4139","ARCT","CF","LENZ","BK4588","BK4505","BK4585","HCSG","BK4137"],"gpt_icon":0},{"id":"2484198881","title":"Silence Therapeutics presents late-breaking Phase 2 zerlasiran data at AHA","url":"https://stock-news.laohu8.com/highlight/detail?id=2484198881","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484198881?lang=en_us&edition=fundamental","pubTime":"2024-11-19 03:35","pubTimestamp":1731958505,"startTime":"0","endTime":"0","summary":"Silence Therapeutics (SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA, or siRNA, in ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silence-therapeutics-presents-late-breaking-phase-2-zerlasiran-data-at-aha?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silence-therapeutics-presents-late-breaking-phase-2-zerlasiran-data-at-aha?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","BK4588","RNA","SLN","LENZ","BK4505"],"gpt_icon":0},{"id":"2483493371","title":"BRIEF-Cofactor Genomics Expands Clinical Use Of Oncoprism, As Their AI Enabled RNA Test Achieves National Clinical Validation After Predicting Immunotherapy Response In Lung Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2483493371","media":"Reuters","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483493371?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:13","pubTimestamp":1731679981,"startTime":"0","endTime":"0","summary":"Nov 15 (Reuters) -    * COFACTOR GENOMICS EXPANDS CLINICAL USE OF ONCOPRISM, AS THEIR AI ENABLED RNA TEST ACHIEVES NATIONAL CLINICAL VALIDATION AFTER PREDICTING IMMUNOTHERAPY RESPONSE IN LUNG CANCER PATIENTSSource text:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA","NHLD"],"gpt_icon":0},{"id":"2483937505","title":"Wave Life Sciences to Present at Jefferies London Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2483937505","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483937505?lang=en_us&edition=fundamental","pubTime":"2024-11-15 21:30","pubTimestamp":1731677400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Nov.  15, 2024  (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/15/2981998/0/en/Wave-Life-Sciences-to-Present-at-Jefferies-London-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","HCSG","BK4588","BK4137","BK4139","BK4585","RNA"],"gpt_icon":0},{"id":"2483337763","title":"Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2483337763","media":"GlobeNewswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483337763?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:05","pubTimestamp":1731618300,"startTime":"0","endTime":"0","summary":"—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset— —Joint poster with Bachem demonstrates superiority of Company’s double-stranded RNA ligases compared t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981613/24825/en/Codexis-Unveils-Pioneering-Enzymatic-Synthesis-Data-to-Enable-the-Future-Manufacturing-of-RNAi-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4135","LENZ","CDXS","IE00BHPRN162.USD","ECO","BK4144","BK4585","RNA","LU0997586861.USD","BK4588","WT","BK4121","BK4139"],"gpt_icon":1},{"id":"2483331111","title":"Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2483331111","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483331111?lang=en_us&edition=fundamental","pubTime":"2024-11-15 03:16","pubTimestamp":1731611760,"startTime":"0","endTime":"0","summary":"As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory updates. Novavax NVAX was in focus this week as investors were disappointed with the lowered guidance.Novavax incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1.26 per share.Revenues in the quarter amounted to $85 million, which beat the Zacks Consensus Estimate of $57 million. However, the top line declined 55% on a year-over-year basis.Novavax also announced that the FDA has lifted the clinical hold on its two pipeline programs, COVID-19-Influenza Combination  and stand-alone influenza vaccine candidates. The agency had initially placed this hold after a study participant who took the CIC shot as part of a phase II study reported nerve damage. With this hold removed, management is working with study investigators and other partner","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-nvax-q3-191600128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","RNA","BK4505","BK4161","CR","NVAX","BK4585","SNDX","BK4568","BK4547","BK4588"],"gpt_icon":0},{"id":"2483280042","title":"RNA Stock Hits Record High on Entering the Cardiac Disease Space","url":"https://stock-news.laohu8.com/highlight/detail?id=2483280042","media":"Zacks","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483280042?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:36","pubTimestamp":1731591360,"startTime":"0","endTime":"0","summary":"Shares of Avidity Biosciences RNA rose more than 12% on Wednesday after the company announced that it is expanding its current RNA-based pipeline of rare muscle disordersto explore a new therapeutic area — precision cardiology.Avidity Enters the Cardio Space With Two New Drugs. The company has decided to advance two new wholly-owned pipeline drugs, AOC 1086 and AOC 1072, targeting two rare genetic cardiomyopathies, PLN cardiomyopathy and PRKAG2 syndrome, respectively.There is currently no FDA-approved therapy for PLN cardiomyopathy and PRKAG2 syndrome, which are caused by mutations in the PLN and PRKAG2 genes, respectively. An excess build-up of these genes can lead to arrhythmias, sudden cardiac arrest, heart failure and other complications.Per management, both AOC 1086 and AOC 1072 have been designed to address the root causes of the genetic diseases. Based on preclinical studies conducted by Avidity, both drugs have demonstrated robust delivery of siRNA  against targets in the heart","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rna-stock-hits-record-high-133600089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNA","BK4532","CSTL","BIIB","IE00B19Z9Z06.USD","LU0109394709.USD","LU0234570918.USD","BK4139","IE00B19Z9P08.USD","BK4585","BK4196","BK4588","LU0889565916.HKD","BK4505","BK4533","LU0320765992.SGD","IE00B894F039.SGD"],"gpt_icon":0},{"id":"2483831192","title":"Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News","url":"https://stock-news.laohu8.com/highlight/detail?id=2483831192","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483831192?lang=en_us&edition=fundamental","pubTime":"2024-11-14 00:24","pubTimestamp":1731515081,"startTime":"0","endTime":"0","summary":"Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space.","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2022/12/Stock-aviditybiosciences-01-shutt-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2022/12/Stock-aviditybiosciences-01-shutt-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/avidity-biosciences-stock-cardiovascular-disease-bristol-myers-squibb/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4588","LU0225284248.USD","LU1093756325.SGD","LU0456855351.SGD","LU1670711040.USD","BK4139","LU1430594728.SGD","IE00BJJMRZ35.SGD","LU0985481810.HKD","LU1670710661.SGD","IE00BSNM7G36.USD","LU0225771236.USD","IE0009355771.USD","IE00BJT1NW94.SGD","LU1093756168.USD","BK4585","LU1291159041.SGD","BK4534","BK4559","LU2125154778.USD","LU0306806265.USD","LU0237698245.USD","BMY","LU1032466523.USD","LU1585245621.USD","BK4532","LU1074936037.SGD","LU1571399168.USD","LU2133065610.SGD","LU0882574055.USD","IE0002141913.USD","LU1670710588.SGD","BK4007","LU1261432733.SGD","IE00BFTCPJ56.SGD","LU2242652126.USD","LU0868494617.USD","LU2360032135.SGD","LU2125154935.USD","LU0306807586.USD","LU0321505868.SGD","BK4581","LU2242646821.SGD","RNA","LU0061475181.USD","LU1718418525.SGD","LU0321505439.SGD","IE00B2B36J28.USD","LU0114720955.EUR","BK4505"],"gpt_icon":0},{"id":"2483071512","title":"Avidity Biosciences (RNA) Gets a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2483071512","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483071512?lang=en_us&edition=fundamental","pubTime":"2024-11-13 18:16","pubTimestamp":1731493006,"startTime":"0","endTime":"0","summary":"Barclays analyst Gena Wang maintained a Buy rating on Avidity Biosciences (RNA – Research Report) today and set a price target of $63.00. The compa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/avidity-biosciences-rna-gets-a-buy-from-barclays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/avidity-biosciences-rna-gets-a-buy-from-barclays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","RNA","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"2483707964","title":"Avidity Biosciences Price Target Maintained With a $60.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2483707964","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483707964?lang=en_us&edition=fundamental","pubTime":"2024-11-13 18:07","pubTimestamp":1731492420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 05:07 ET (10:07 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA"],"gpt_icon":0},{"id":"2483025046","title":"Promising Outlook for Avidity Biosciences: Strategic Focus on Genetic Targeting and Innovative AOC Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2483025046","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483025046?lang=en_us&edition=fundamental","pubTime":"2024-11-13 15:35","pubTimestamp":1731483310,"startTime":"0","endTime":"0","summary":"In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Avidity Biosciences (RNA – Research Report), with a price ta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-avidity-biosciences-strategic-focus-on-genetic-targeting-and-innovative-aoc-technology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-avidity-biosciences-strategic-focus-on-genetic-targeting-and-innovative-aoc-technology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4121","GENE","BK4585","BK4588","BK4505","RNA"],"gpt_icon":0},{"id":"2483093463","title":"PYC Therapeutics to Unveil Pioneering RNA Therapy Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2483093463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483093463?lang=en_us&edition=fundamental","pubTime":"2024-11-13 08:19","pubTimestamp":1731457172,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics, a clinical-stage biotech firm focused on RNA therapies, is poised to re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-to-unveil-pioneering-rna-therapy-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-to-unveil-pioneering-rna-therapy-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BK4139","LENZ","RNA","BK4505"],"gpt_icon":0},{"id":"2483053778","title":"Buy Rating Affirmed for Avidity Biosciences Amid Precision Cardiology Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2483053778","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483053778?lang=en_us&edition=fundamental","pubTime":"2024-11-13 03:25","pubTimestamp":1731439511,"startTime":"0","endTime":"0","summary":"In a report released today, Joseph Stringer from Needham maintained a Buy rating on Avidity Biosciences (RNA – Research Report), with a price targe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-avidity-biosciences-amid-precision-cardiology-advancements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-avidity-biosciences-amid-precision-cardiology-advancements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aviditybiosciences.com","stockEarnings":[{"period":"1week","weight":-0.1483},{"period":"1month","weight":-0.1017},{"period":"3month","weight":-0.0221},{"period":"6month","weight":0.5505},{"period":"1year","weight":5.8756},{"period":"ytd","weight":3.7028}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.003796},{"month":2,"riseRate":0.75,"avgChangeRate":0.142853},{"month":3,"riseRate":0.5,"avgChangeRate":0.008776},{"month":4,"riseRate":0.25,"avgChangeRate":-0.099421},{"month":5,"riseRate":0.5,"avgChangeRate":-0.010872},{"month":6,"riseRate":1,"avgChangeRate":0.162259},{"month":7,"riseRate":0.4,"avgChangeRate":-0.025313},{"month":8,"riseRate":0.6,"avgChangeRate":0.033831},{"month":9,"riseRate":0.4,"avgChangeRate":-0.044821},{"month":10,"riseRate":0,"avgChangeRate":-0.12124},{"month":11,"riseRate":0.6,"avgChangeRate":0.10837},{"month":12,"riseRate":0.75,"avgChangeRate":0.245496}],"exchange":"NASDAQ","name":"Avidity Biosciences, Inc.","nameEN":"Avidity Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avidity Biosciences, Inc.(RNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avidity Biosciences, Inc.(RNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avidity Biosciences, Inc.,RNA,Avidity Biosciences, Inc.股票,Avidity Biosciences, Inc.股票老虎,Avidity Biosciences, Inc.股票老虎国际,Avidity Biosciences, Inc.行情,Avidity Biosciences, Inc.股票行情,Avidity Biosciences, Inc.股价,Avidity Biosciences, Inc.股市,Avidity Biosciences, Inc.股票价格,Avidity Biosciences, Inc.股票交易,Avidity Biosciences, Inc.股票购买,Avidity Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avidity Biosciences, Inc.(RNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avidity Biosciences, Inc.(RNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}